



# The Baltic Paediatric Congress

**L** LATVIJAS  
**PEDIATRU**  
ASOCIĀCIJA




August 19-21, 2015  
Riga, Latvia

[www.bpc2015.eu](http://www.bpc2015.eu)

# PROGRAMME

# EXHIBITION PLAN



# CONTENTS

GENERAL INFORMATION .....	3
ORGANIZERS .....	5
PRELIMINARY PROGRAMME .....	6





“Children are  
flowers in the garden  
of God, entrusted to us,  
to love and care...”

/Zenta Maurina/



Dear Colleagues,

On behalf of the Latvian Paediatric Association, we would like to welcome you to Riga.

The Programme Committee has created a comprehensive series of keynote lectures, symposia, educational workshops and meet-the-professor sessions, covering the entire field of paediatric related diseases and involving a large number of internationally renowned experts. The programme includes regular interactive presentations highlighting the results of applied research and the lessons learned in clinical and laboratory practice that will allow for an exchange of experiences among the various sub-specialties.

You will not only benefit from scientific exchanges taking place during the formal activities, but also networking with colleagues from different backgrounds encourages new research ideas and innovative ways of organising laboratory and clinical processes. The programme provides an unique opportunity for debate, discussion and the exchange of important ideas. In addition, your

contributions are highly appreciated and will be presented in oral sessions or poster sessions that will undoubtedly extend our knowledge of the latest scientific developments in these fields.

Beyond everything the scientific programme has to offer, we know that in Riga, our host city, you will discover a city that is modern and traditional, vibrant and diverse, hospitable and unforgettable. Riga today is a city where sustainability, growth, and quality of life go hand in hand very well. Visitors to Riga are captured by the city's spirit and will leave it inspired and full of new ideas. We wish you a fruitful Baltic Paediatric Congress 2015 Meeting and a great time in Riga.

**Asoc.prof. Ilze Grope**

*President of Latvian Paediatric Association*

# GENERAL INFORMATION

## VENUE

Riga Stradins University  
Dzirčiema street 16, Riga  
Riga, Latvia

## HOW TO REACH THE UNIVERSITY?

From Old Town hotels use tram Nr.4 from station "Griņinieku iela" and get off at station "Dzirčiema iela" (8th stop).

If you buy the ticket in the tram, it costs 2,00 EUR.

If you buy the e-coupon at "Narvesen", it costs 1,15 EUR.

From Radisson blu Daugava hotel use tram Nr. 4, station "Nacionālā Bibliotēka" and get off at station "Dzirčiema iela" (7th stop).

If you buy the ticket in the tram, it costs 2,00 EUR.

If you buy the e-coupon at "Narvesen", it costs 1,15 EUR.

## CONGRESS LANGUAGE

English is the official language of the Congress

Most of the sessions will be translated into Latvian language

## REGISTRATION AND INFORMATION DESK WORKING HOURS:

Wednesday, August 19th , 14:30-17:00

Thursday, August 20th , 07:30-18:00

Friday, August 21st, 07:30-18:00

## CONGRESS PRESENTATIONS

Speakers are kindly advised to upload the presentations in advance.

Please, check your presentation before the session at the IT assistant in the congress hall or Registration desk.

For the free paper sessions be prepared for a 7 minute power point presentation + about 3 minute discussion.

## POSTER PRESENTATIONS

Please hand in your poster to the registration desk on wither August 19 from 14:30-17:00 or August 20th from 07:30-09:00

Poster session is scheduled during the lunch times on 20th and 21st of Augusts.

Poster authors are advised to be present at his/her poster during the poster session!

## CERTIFICATE OF ATTENDANCE

Certificate of Attendance will be issued to all registered participants.

Participants attending the whole Congress will receive certificate accredited by European Accreditation Council for Continuing Medical Education (EACCME) after completing the evaluation form sent to your e-mail after the Congress.

Participants attending separate sessions only will receive their certificate wither by e-mail or from EVISIT database.

## CONGRESS ID CARDS

ID card is included in the Congress materials and have to be worn at all times and premises during the Congress.

## RECEPTION HELD BY RECTOR OF THE UNIVERSITY OF LATVIA, August 19th, 18:00-20:00

Venue: Small Hall (University of Latvia, Raina Boulevard 19, Riga)

At the reception, guests will be introduced to medical studies and research, including development of paediatric sector at the University of Latvia. Enjoying a glass of wine and appetizers, the guests will be able to exchange thoughts on current events in the paediatric sector.

## **GET – TOGETHER,**

**August 20th, 18:00-20:00**

Welcome reception will be held August 20th at 18:00 in the Botanical Garden of the University of Latvia. Congress assistants will kindly guide you to the Garden as it is a walking distance from the University

## **GALA DINNER**

**(additional cost of 50.00 EUR),**

**August 21st, 19:00-22:00**

Venue: Restaurant LightHouse Jurmala, 1a Gulbenes street

Restaurant LightHouse Jurmala is located on the shore of Gulf of Riga.

Menu offers a wide variety of mediterranean values, mixed with local homemade products, provided by this region.

Juicy meat, seafood, vegetables – with taste of crisp and smoke, prepared on Spanish charcoal grill 'Josper' – brings a new meaning to the word gourmand. All of this can be fulfilled sitting on terrace of LightHouse enjoying gorgeous sunsets.

Event programme:

19:00 Departure by bus from Riga Stradins University

19:30 Seated dinner

20:30 Background & Dancing music by Diana Pirags.

Networking

## **LUNCHES AND COFFEE BREAKS**

**(included in the registration fee of participants attending the whole Congress)**

Lunches and coffee will be served in the cafeteria of Riga Stradins University. Lunch coupons will be given during the registration together with your ID card.

## **VIDEO RECORDING**

Some of the lectures will be recorded and available to our delegates after the Congress

**Taxi – (+371) 20008500**

**Emergency – 112**

## **CME credits**

We are pleased to inform you that your application for European accreditation for:

7th Baltic Congress of Anaesthesiology and Intensive Care

(Hotel Radisson Blu Latvija, Riga, Latvia, 4.–6.12.2014)

Event code: 10856

was granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).



## **SECRETARIAT AND**

## **TECHNICAL ORGANIZERS**

**(sponsorship, exhibition, travel services)**

Liga Hartpenga or Mara Barbare Con-Ex Latvia Tours group

Aspazijas blvd. 24-10, Riga, LV-1050

Phone: office: +371 67085082

E-mail: info@bpc2015.eu

# ORGANIZERS

## CONGRESS IS ORGANIZED BY



Latvian Paediatric association



Estonian Paediatric association



Lithuanian Paediatric association



RĪGA STRADIŅŠ  
UNIVERSITY



LATVIJAS  
UNIVERSITĀTE  
ANNO 1919



BĒRNU PALIATĪVĀS APRŪPES BIEDRĪBA

## CONGRESS PRESIDENT:

Asoc. prof. Ilze Grope

## CONGRESS VICE-PRESIDENTS:

Prof. Arunas Valiulis (LT)

Dr. Liis Toome (EE)

Dr. Kaja Julge (EE)

## ORGANIZING COMMITTEE

### Iveta Dzivite-Krisane (LV)

Chair of the organizing committee

Dace Gardovska (LV)

Ingrida Rumba-Rozenfelde (LV)

Vallo Tillmann (EE)

Liis Toome (EE)

Arunas Valiulis (LT)

Dace Zavadska (LV)

Arta Barzdina (LV)

Elina Aleksejeva (LV)

Anda Jansone (LV)

Zanete Ilzina (LV)

Zane Līkopa (LV)

Marita Cikovska (LV)

Urzula Nora Urbane (LV)

## SCIENTIFIC COMMITTEE

### Jana Pavare (LV)

Chair of the scientific committee

Enoks Bikis

Iveta Dzivite – Krisane

Ineta Grantina

Margarita Krauca

Daiga Kviluna

Inguna Lubaua

Vizma Meiksane

Evija Palceja

Ieva Pukite

Dita Raiska

Amanda Smildzere

Renate Snipe

Valda Stanevica

# PRELIMINARY PROGRAMME

## OF THE 3<sup>rd</sup> BALTIC PAEDIATRIC CONGRESS

August 19th – 21st, 2015

Riga Stradins University (Riga, Latvia)

PRE-CONGRESS			
AUGUST 19TH			
14:30-18:00	Registration		
09:30-11:30	Paediatric Studies in Baltic States (invited guests)	Hall Senats (RSU)	
	Moderator: Prof. D. Gardovska (LV)		
11:30-12:15	Lunch (invited guests)		
12:15-13:00	Reception held by Rector of the Riga Stradins University (invited guests)	Rectoriat (RSU)	
13:15-14:30	Introduction to Medical Technology Centre of Riga Stradins University (invited guests)	RSU Medical Education Technology Centre (Anninmuizas Boulevard 26a, Riga)	
	Moderators: R. Razgalis (LV), V. Krumina (LV)		
WORKSHOPS			
Hall Hippocrates		Hall Senats	Hall Auditorium I
15:00-17:00	Children’s Palliative Care. A Multidisciplinary Approach.	Sepsis Workshop and Net Foundation	Breastfeeding
	Moderators: dr. A. Jansone (LV), A.Garchakova (BY)	Moderators: Prof. D. Gardovska (LV), Assist. Prof. J. Pavare (LV), Asoc. Prof. I. Grope (LV)	Latvian Lactation Consultant Association (In Latvian language)
	Human Rights, ethics and concepts in children’s palliative care. A. Garchakova (BY) – 15’		Low milk supply – 10 problems and 10 solutions. Specialist’s recommendations to a family doctor.



	Children's palliative care in Latvia: Past, present and future. <b>A. Jansone (LV) – 10'</b>		
	Essentials of pain management in paediatric palliative care. <b>I. Voitovica (LV) – 10'</b>		
	Specific aspects of nutrition for children living with life-limiting, life-threatening conditions. <b>D. Fridrihsone (LV) – 10'</b>		
	What do spirituality and spiritual care have to do with health, illness, pain, death and grief? <b>A. Briede (LV) – 10'</b>		
	Engaging the family: what families tell us? <b>V. Drande (LV) – 10'</b>		
	Children palliative care in Liepaja district – 3 years of new experience. <b>J. Cirule (LV) – 10'</b>		
<b>18:00-20:00</b>	<b>Reception held by Rector of the University of Latvia</b>	Small Hall (University of Latvia, Raina Boulevard 19, Riga)	
<b>AUGUST 20TH</b>			
<b>07:30-18:00</b>	<b>Registration</b>		
<b>07:30-08:00</b>	<b>Coffee</b>		
	<b>Hall Aula</b>	<b>Hall Hippocrates</b>	<b>Hall Auditorium I</b>
<b>08:00-09:30</b>		Ipsen Satellite Symposium <b>Maximizing treatment benefit for children with diarrhea and constipation</b>	Silvanols Morning Mini Symposium <b>Beyond current RTI treatments: new ways to recovery</b>
		Welcome and introduction (Ipsen Pharma)	<b>Moderator: Prof. A. Valiulis (LT)</b>
		Simple, unique approach to treat diarrhea. <b>Assoc. Prof. I. Grope (LV)</b>	Welcome. <b>Prof. A. Valiulis (LT)</b>
		Journey to the bowels in case of diarrhea <b>(3d film)</b>	Asthma in adolescents: shared decision making and other secrets of management. <b>Prof. A. Valiulis (LT)</b>
		Currently recommended treatment of childhood constipation. <b>Assoc. Prof. V. Urbonas (LT)</b>	How long is it acceptable for a child to cough? <b>I. Cirule (LV)</b>
			Our experience: how to treat cough. <b>I. Grisle (LV)</b>

09:30-9:50	<b>CONGRESS OPENING</b> – president of the Congress Assoc. Prof. I. Grope – short performance – Minister of Health of Republic of Latvia, Dr. Guntis Belevics		
9:50-9:55	<b>Presentation by EVISIT</b>		
09:55-11:30	<b>Actualities in Children's Health</b>	<b>Rare Diseases</b>	
	<b>Moderators: D. Kviluna (LV), Prof. A. Valiulis (LT), Assoc. prof. I.Grope (LV), Md Phd L.Toome (EE)</b>	<b>Moderators: Z. Krumina (LV)</b>	
	Children's Health in Latvia – where we are and where are we going? <b>Assoc. Prof. I.Grope (LV) – 10'</b>	Mucopolysaccharidoses, Gaucher and Fabry diseases as a paradigm of rare diseases. <b>Prof. Anna Tylki-Szymanska (PL)</b>	
	Lifestyle Survey of Doctors, Medical Residents and Medical Students in Latvia. <b>N.U. Urbane (LV) – 10'</b>	Blue Rubber Bleb Nevus Syndrome: A Rare Cause of Iron Deficiency Anaemia. <b>K. Saare (EE)</b>	
	Children's Health in Estonia. <b>MD PhD L.Toome (EE) – 15'</b>		
	Lithuania as mirror of diversity of child health care in Central-Eastern Europe. <b>Prof. A.Valiulis (LT) – 15'</b>		
	How to involve parents in improvement tactics regarding patient safety? <b>K. Illy (NL) – 20'</b>		
	Optimized therapy in JIA – where do we stand? <b>Prof. D. Foell (DE) – 20'</b>		
11:30-11:45	<b>Coffee</b>		
	<b>Hall Hippocrates</b>	<b>Hall Auditorium I</b>	<b>Hall Auditorium II</b>
11:45-13:30	<b>Actualities in Paediatrics – Severe Infectious Diseases and Immunodeficiency – I (coffee and snacks will be served)</b>	<b>Rare Diseases</b>	<b>Pulmonology &amp; Allergology</b>
	<b>Moderator: Assist. Prof. J.Pavare (LV), Prof. D. Gardovska (LV), Assist. Prof. O. Sabelnikovs (LV)</b>	<b>Moderators: Z.Krumina (LV)</b>	<b>Moderators: I. Grantina (LV), Prof. A. Valiulis (LT)</b>

	Paediatric sepsis. <b>V.Stefánsson Thors (IS) – 20'</b>	Homocystinurias and Methylation Disorders. <b>Prof. H. J. Blom (DE)</b>	Sublingval allergen specific immunotherapy. <b>B. Robin (FR) – 20'</b>
	Sepsis in critically ill children. <b>Prof. M. Peters (UK) – 30'</b>	Rare diseases patient cases in LV. <b>Z. Krumina (LV)</b>	Food allergy in children, OFCT – Latvian experience. <b>E. Aleksejeva (LV) – 15'</b>
	Fluid management and Hemodynamic Support in critically ill children. <b>Prof. M. Peters (UK)- 45'</b>		Skin infections in children with atopic dermatitis. <b>Assoc. Prof. O. Rudzeviciene (LT) – 15'</b>
	Discussion – <b>10'</b>		H1-antihistamines – Present and future on antihistamines in Paediatrics. <b>Prof. E. Valovirta (FI) – 20'</b>
			Preschool wheezing as key for novel understanding of asthma. <b>Prof. A. Valiulis – 15'</b>
<b>13:30-14:00</b>	<b>Lunch &amp; Poster Session</b>		
	<b>Hall Hippocrates</b>	<b>Hall Auditorium I</b>	<b>Hall Auditorium II</b>
<b>14:00-15:30</b>	<b>Patient Safety</b>	<b>Rare Diseases</b>	<b>Free Papers</b>
	<b>Moderator: E. Palceja (LV), K. Illy (NL)</b>	<b>Moderator: E. Aleksejeva (LV), L. Syderius (NL)</b>	<b>Moderator: A. Barzdina (LV)</b>
	Intoduction – <b>5'</b>	European forecast for community and primary care in paediatrics. <b>Prof. M. Katz (IL) – 30'</b>	Acute kidney injury – an underestimated problem in the paediatric intensive care. <b>J. Krastins (LV) – 10'</b>
	Patient's safety aspects in acute setting of paediatrics. <b>E. Palceja (LV) – 15'</b>	Towards harmonization of coordinated care for children with disabling Conditions. <b>L. Syderius (NL)- 30'</b>	Comparison of child and parent functional somatic symptom reporting amond middle childhood primary care attenders. <b>A. Uzans (LV) – 10'</b>
	Why do things go wrong and how can we learn from these incidents? <b>K. Illy (NL) – 30'</b>	Cystic fibrosis. Latvian experience. <b>V.Svabe (LV) – 25'</b>	Clara cell protein 16 (CC16) gene polymorphism and the risk of asthma development in children: a meta-analysys. <b>O. Cirstea (MD) – 10'</b>
	Correct use of antibiotics. Clin.Farm. <b>I.Sviestina (LV) – 15'</b>	Discussion – <b>5'</b>	The changes of fluid management in paediatric patients with head trauma from 2004 to 2014 in Children's Clinical University Hospital. <b>R. Gobergs (LV) – 10'</b>

	Patient safety aspects a the Lapland Central Hospital. <b>L. Rautiainen (FI) – 10’</b>		
	Discussion – <b>15’</b>		
15:30-16:00	Coffee		
	Hall Hippocrates	Hall Auditorium I	Hall Auditorium II
16:00-17:30	Paediatric Rheumatology	Paediatric Gastroenterology	Paediatric Endocrinology
	<b>Moderators: Prof. V. Stanevica (LV), Prof. D. Foell (DE)</b>	<b>Moderators: I. Pukite (LV), E. Aleksejeva (LV), Asoc. Prof. V. Urbonas (LT)</b>	<b>Moderators: Assist.Prof. I.Dzivite-Krisane (LV), Prof. V. Tillmann (EE), Prof. R.Verkauskiene (LT)</b>
	Highlights on paediatric rheumatology. <b>Prof. D. Foell (DE) – 45’</b>	Home parenteral nutrition in children: long-term experience in Poland. <b>Prof. J. Ksiazuk (PL) – 60’</b>	Growth and puberty in chronic disease: are we doing better? <b>Prof. P. Czernichow (FR) – 45’</b>
	TML involment in JIA patients. <b>Z.Davidsone (LV) – 20’</b>	Parenteral nutrition in children: Latvian experience. <b>I. Pukite (LV) – 15’</b>	High prevalence of prop1 defects in Lithuania: phenotypic findings in an ethnically homogenous cohort of patients with multiple pituitary hormone deficiency. <b>Prof. R. Verkauskiene (LT) – 20’</b>
	Case report. <b>A. Lazareva (LV) – 20’</b>	Enteral nutrition in the treatment of Crohn’s disease. <b>V. Urbonas (LT) – 15’</b>	Intrauterine and postnatal growth in children with Hla-conferred susceptibility to type 1 diabetes. <b>Prof. V. Tillmann (EE) – 20’</b>
	Discussion	Discussion	Discussion
18:00	Welcome reception at the Botanical Garden of the University of Latvia (walking distance)		
21ST AUGUST			
07:30-18:00	Registration		
07:30-09:00	Coffee		
	Hall Hippocrates	Hall Auditorium I	Hall Auditorium II
08:00-09:00			Olainfarm Morning Symposium
			From witch’s hammer and filthy pig to noofen or modern approach to tics. <b>J. Strautmanis (LV)</b>
08:55-09:00			Welcome words from the Children’s Hospital Foundation

09:00-09:30		<b>Congress Lecture</b>	Chronic urticaria problem – finally the light at the end of the tunnel? <b>M. Bukovskis (LV)</b>
		Innovations of basic sciences: stem cells and their role in the treatment of paediatric cardiac failure – opportunities and challenges. <b>Prof. A. Lacis (LV)</b>	
09:30-12:00	<b>General Problems of Children and Adolescent's Health</b>	<b>Actualities in paediatrics – Severe Infectious Diseases and Immunodeficiency II</b>	
	<b>Moderators:</b> <b>Prof. I. Rumba-Rozenfelde (LV),</b> <b>Prof. D.Puras (United Nations)</b>	<b>Moderator: Prof. D. Gardovska (LV),</b> <b>N. Kurjane (LV)</b>	
	TBE in children – a risk of long-term neurologic and psychosocial complications. <b>M. Sundin (SE) – 30'</b>	Basics of the immune system – a practical approach to evaluation of suspected immunodeficiencies. <b>Prof. Á.Haraldsson (IS) – 40'</b>	
	Right to health in adolescence – modern understanding and role of paediatrics. <b>D.Puras, UN Special Rapporteur on the Right to Health (UN) – 30'</b>	Infection of the immunocompromised children. <b>V. S. Thors (IS) – 30'</b>	
	Advances in understanding and treating attention deficit hyperactivity disorder (ADHD). <b>N. Bezborodovs (LV) – 20'</b>	Multiple Organ Failure: Adverse, Adaptive or "Antifragile". <b>Prof. M. Peters (UK) – 30'</b>	
	Adolescent eating behavior. <b>D. Santare (LV) – 20'</b>	Biomarkers diagnostic and prognostic value in the Paediatric ICU. <b>Prof. C. Rey (ES) – 40'</b>	
	Child health from human rights perspective in light of reporting process to United Nations. <b>I. Ebela (LV) – 20'</b>		
	Effectiveness of multisensory therapy in treatment of children with delayed speech and language development. <b>V. Folkmanis (LV) – 20'</b>		
	Discussion – <b>10'</b>		




12:00-14:00	Lunch & Poster Session		
	Hall Hippocrates	Hall Auditorium I	Hall Auditorium II
13.00-14.00	<b>Industry Symposium – Pfizer</b>		
	Overview of PCV13 and its impact worldwide. <b>S.Castro Marques (PT)</b>		
	Pneumococcal paediatric vaccination: learnings from the Nordics and Baltic countries. <b>H. Ahman (F)</b>		
14.00-15.30	<b>Paediatric Infectious Diseases – Community Acquired Pneumonia</b>	<b>Paediatric Cardiology</b>	<b>Neonatology</b>
	<b>Moderator: Assoc. Prof. I. Grope (LV), Prof. A. Valiulis (LT)</b>	<b>Moderator: Assist. Prof. I. Lubaua (LV), Prof. A. Lacis (LV)</b>	<b>Moderators: A. Smildzere (LV), L. Tomme (EE)</b>
	CAP in Latvian children – tendencies and importance. <b>Assoc. prof. I. Grope (LV) – 15'</b>	Right aortic arch in the fetus and postnatal outcome. <b>V. Zidere (UK) – 30'</b>	Extremely preterm birth – from assessment to improvement. <b>Prof. M. Norman (SE) – 25'+5'</b>
	Streptococcus pneumoniae – Infections and prevention. The Icelandic Experience. <b>Prof. A. Haraldsson (IS) – 15'</b>	Adult congenital heart disease – Vilnius Experience. <b>L. Gumbiene (LT) – 30'</b>	Antibiotics in NICU: prescribe or not prescribe. <b>A. Liubsys (LT) – 20'</b>
	Serotype distribution of invasive Streptococcus pneumoniae in Lithuania. <b>Dr. M. Janulaitiene (LT)</b>	Supraventricular tachycardia in newborns. <b>E. Ligere (LV) – 15'</b>	Clinical trials in neonates – needed and feasible. <b>T. Metsvaht (EE) – 20'</b>
	From prospective to retrospective – new tool to rule patient with CAP. <b>A. Nikulenкова (LV) – 15'</b>	Nuchal translucency and congenital heart defects in fetuses. <b>Assist. Prof. I. Lubaua (LV) – 10'</b>	Therapeutic hypothermia in Latvia. <b>A. Juras, S. Stanke (LV) – 15'</b>
	Discussion – <b>10'</b>	Discussion	Family-Centered Care In Neonatal Intensive Care Units (Nicus) In Estonia: Results From International Closeness Survey. <b>L. Toome (EE) – 15'</b>
	Management of community acquired pneumonia in children: Nordic vs real life approach. <b>A. Valiulis (LT) – 20'</b>		Transposition of the great arteries in neonates: incidence and outcome. <b>A. Smildzere (LV) – 15'</b>

15:30-15:00	Coffee		
	Hall Hippocrates	Hall Auditorium I	Hall Auditorium II
15:45-18:00	Regional Problems in Immunization – Similarities and Differences in Baltic Countries’ NIP	Challenges in Primary Health Care	Current Problems in Paediatric Nursing
	<b>Moderators:</b> <b>Assist. Prof. D. Zavadska (LV),</b> <b>Prof. T. Vesikari (FI), Prof. Haraldsson (IS)</b>	<b>Moderators: R. Snipe (LV),</b> <b>V. Meiksane (LV), M. Krauca (LV)</b>	<b>Moderator: D. Raiska (LV)</b>
	Influenza vaccination strategies in children. <b>Prof. T. Vesikari (FI) – 30’</b>	Children’s primary health care in paediatrician and GP’s view. <b>L. Zaharova (LV) – 20’</b>	The prevention of infections establishing care protocol CVC within nurse in care. <b>L. Fridenberg (LV)</b>
	The burden of and vaccination against influenza in children – Iceland experience. <b>V. Stefansson Thors (IS) – 15’</b>	Who comes to the paediatrician in emergency department of Children’s Clinical University Hospital and why? <b>A. Lazareva (LV) – 20’</b>	The provision of oxygen newborn in intensive care. <b>I. Damberga (LV)</b>
	Childhood immunisation – The Icelandic Saga. <b>Prof. A. Haraldsson (IS) – 15’</b>	New trends and tendencies in outpatient practice in Riga. <b>V. Meiksane (LV) – 15’</b>	Otitis for children. Our experience in nursing care. <b>A. Voicehovska (LV)</b>
	Reliance on health care providers and attitude towards vaccination among mothers. <b>D. Isarova (LV) – 15’</b>	Hospital emergency department role in children’s primary health care. <b>S. Burokiene (LT) – 30’</b>	The model of palative care of children evaluation in Latvia. <b>I. Kalnina (LV)</b>
	Immunization impact on epidemiology of infectious diseases in Latvia. <b>J. Perevoscikovs (LV) – 30’</b>		Nursing care of paediatric patient with diabetes. <b>I. Veilande (LV)</b>
	Pertussis epidemiology in Estonia. <b>P.Jogi (EE) – 15’</b>		Development of the child care in the nursing practice. <b>D. Raiska (LV)</b>
	Sweden Attitude to vaccination, before and after Pandemrix® and narcolepsy event in Sweden. <b>M.Zusmanis (SE) – 15’</b>		
18:00	Closing of the Congress		
19:00	Departure for Congress Dinner (additional payment of 50 EUR payable until August 15th)		



# KAS IR VĒJBAKAS?

Vējbakas ir ļoti lipīga slimība, ko ierosina *Varicella zoster* vīruss, kas inficē elpceļus<sup>1</sup>



## KURŠ IR PAKĻAUTS VĒJBAKU RISKAM?

Lai gan vējbakas tiek uzskatītas par bērnu slimību, **IKVIENS** ir pakļauts to riskam. Atsevišķas grupas slimība apdraud īpaši nopietni:<sup>2</sup>



## KĀ IESPĒJAMS PASARGĀTIES NO VĒJBAKĀM?



**VAKCINĀCIJA**  
PASARGĀ NO  
**VĒJBAKĀM**<sup>3,4</sup>



Aplēses liecina, ka vakcinācijas iekļaušana imunizācijas programmā **samazina saslimšanas gadījumu** skaitu

**89%**<sup>4</sup>

PĀRSLIMOTAS VĒJBAKAS, **VISTICAMĀK, NODROŠINĀS IMUNITĀTI** PRET TURPMĀKIEM INFICĒŠANĀS GADĪJUMIEM<sup>2</sup>

Ja infekcija piemeklējusi jūsu pacientus, sniedziet šos padomus, kā ierobežot slimības izplatību:<sup>5</sup>



Neļaujiet inficētajam doties uz bērnudārzu, skolu vai darbu



Izvairieties no kontakta ar riska grupām



Tīriet virsmas ar dezinficējošu šķidrumu



Regulāri mazgājiet inficēto apģērbu un gultas veļu

## KO TĀLĀK?



**REKOMENDĒJIET LABĀKO**  
**AIZSARDZĪBU PRET VĒJBAKĀM**



1. World Health Organization. Weekly Epidemiological Record No 25. 2014;89:265-88. 2. Centers for Disease Control and Prevention. Varicella. In: Epidemiology and prevention of vaccine-preventable diseases, 12<sup>th</sup> edn. Washington DC, USA: Public Health Foundation. 2012:301-324. Available at: <http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/varicella.pdf>. (Last accessed: June 2014). 3. Bonanni P, Breuer J, Gershon A *et al*. Varicella vaccination in Europe - taking the practical approach. *BMC Med*. 2009;7:26. 4. Centers for Disease Control and Prevention. Impact of Vaccines in the 20<sup>th</sup> & 21<sup>st</sup> Centuries. Available at: <http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/G/impact-of-vaccines.pdf>. (Last accessed: June 2014). 5. NHS Choices. Chickenpox – Prevention. Available at: <http://www.nhs.uk/Conditions/Chickenpox/Pages/Prevention.aspx> (Last accessed: June 2014)

**TREAT  
THE INFECTION  
SMARTLY**



## Furamags®

*Furaginum solubile*

25 mg capsules N30  
50 mg capsules N30

**For the treatment and prophylaxis of urinary tract infections**

### Use of Furamags®:

- ▶ Treatment of urinary tract infections – cystitis, urethritis, pyelonephritis
- ▶ Treatment of relapsing urinary tract infections
- ▶ Prophylaxis of relapsing urinary tract infections
- ▶ Prophylaxis of urinary tract infections – before and after urological surgeries and manipulations
- ▶ Prostatitis treatment
- ▶ Treatment of gynaecological infections

For adults and children from the age of 1 year.

Prescription drug. Furamags® drug description. Approved by the SAM on 13.03.2014.



## Noofen®

*Phenibutum*

250 mg tablets N20

**For a lasting joy of living!**

**Has an effect already on the first day of using!**

### Use of Noofen®:

- ▶ Reduces the symptoms of asthenia
- ▶ Increases the focus
- ▶ Improves the memory
- ▶ Raises the personal interest and the initiative
- ▶ Reduces headache
- ▶ Reduces the feeling of heaviness in the head
- ▶ Improves sleep

Does not cause habituation, the development of addiction and the syndrome of coming off.

Prescription drug. Noofen® drug description. Approved by the SAM on 23.08.2012.



## Fenkarol®

*Quifenadini hydrochloridum*

10 mg tablets N20  
25 mg tablets N20  
50 mg tablets N15

**Antihistamine remedy**

### Use of Fenkarol®:

- ▶ Pollinosis or hay-fever (allergic rhinitis and conjunctivitis)
- ▶ Acute and chronic urticaria
- ▶ Angioneurotic oedema
- ▶ Dermatoses (eczema, neurodermatitis, itch, etc.)
- ▶ Allergy provoked by food or medicine

Fenkarol® blocks H1 histamine receptors and activates enzyme diamine oxidase reducing the concentration of histamine in tissue.

For adults and children from the first days of life.

Non-prescription drug. Fenkarol® drug description.

CREATED BY OLAINFARM  
MADE IN LATVIA

Information for medical professionals.  
Before prescribing, read the full description of the drug.  
Info prepared on 04.08.2015.  
Advertiser: AS "Olainfarm". [www.olainfarm.lv](http://www.olainfarm.lv)

**OlainFarm**



**Dear, Colleagues!**

**JSC "Olainfarm" invites you to  
Satellite Symposium,  
8:00–9:30, 21<sup>st</sup> of August**

**Riga Stradins University, Hall 2**

**Program:**

**1.**

From "witch's hammer" and "filthy pig"  
to Noofen or Modern approach to tics.  
*Jurgis Strautmanis, pediatric neurologist*

**2.**

Antimicrobial resistance trends and  
impact on urinary tract infection treatment.  
*Vladimirs Strazdins, pediatric nephrologist*

**3.**

Chronic urticaria problem –  
finally the light end of the tunnel?  
*Maris Bukovskis, allergologist*

# Baltic Paediatric Congress 2015

## Satellite Symposium

at Riga Stradins University hall Hippocrates 2015 08 20 8:00-9:00

### MAXIMASING TREATMENT BENEFIT FOR CHILDREN WITH DIARRHEA AND CONSTIPATION

#### PROGRAMME

**8:00-8:05**

Welcome and introduction (Ipsen Pharma)



**8:05-8:30**

Simple, unique approach to treat diarrhea

*Assoc. prof. I. Grope (Latvia)*

**8:30-8:35**

Journey to the bowels in case of diarrhea (3D film)



**8:35-9:00**

Currently recommended treatment of childhood constipation

*Assoc. prof. V. Urbonas (Lithuania)*

*Fresh juice will be served before, from 7:30*



With fragrant morning coffee and energizing tee you  
are cordially invited to  
the **Morning symposium** on **August 20th,**  
**7:45** in the **1st Auditorium**

**MANAGEMENT OF CHILD WITH PERSISTENT  
RESPIRATORY SYMPTOMS:  
BREAKING THE VICIOUS CIRCLE**

Chairs Prof. Arunas Valiulis (Vilnius, Lithuania)

08:00 **Welcome**  
Arunas Valiulis (Vilnius, Lithuania)

**Asthma, cough variant asthma, bronchial hyperreactivity  
syndrome in children: shared decision making and other  
secrets of management**

Arunas Valiulis (Vilnius, Lithuania)

**How long is it acceptable for a child to cough?**

Ieva Cirule (Riga, Latvia)

**Our experience: how to treat cough**

Ineta Grisle (Riga, Latvia)

09:20 **Summing-up & final remarks**  
Arunas Valiulis (Vilnius, Lithuania)

A Satellite Symposium Sponsored by Pfizer at the 3rd Baltic Pediatric Congress  
Riga, Latvia  
19 – 21 August, 2015

# INVITATION


## **Pneumococcal Vaccination: Where we are and where we are going**

Friday, 21 August, 2015  
13:00-14:00

Riga Stradins University Hall Hippocrates

**13:00 Overview of PCV13 and its impact worldwide.**  
Dr. Susana Castro Marques (Lisbon, Portugal)

**13:30 Pneumococcal pediatric vaccination:  
learnings from the Nordics and Baltic countries.**  
Dr. Heidi Åhman (Helsinki, Finland)





# Take Steps to Help Protect Infants and Children From Pneumococcal Disease

Prevenar 13\* provides the broadest coverage of any pneumococcal conjugate vaccine (PCV)

Pneumococcal disease remains the leading cause of vaccine-preventable death in children aged <5 years worldwide. Clinical manifestations include invasive disease (meningitis, bacteremia, and bacteremic pneumonia) and noninvasive disease (pneumonia and otitis media [OM]).<sup>1-3</sup>

- Broadest coverage of the serotypes most responsible for pneumococcal disease<sup>4-6</sup>
- The only PCV that includes serotypes 3, 6A, and 19A<sup>4-6</sup>
- Demonstrated real-world effectiveness against invasive pneumococcal disease (IPD), including reduction of serotype 19A IPD in multiple countries<sup>4,8-10</sup>
- Real-world impact on OM<sup>11</sup>
- Significant reductions in hospitalizations due to pneumococcal pneumonia<sup>12-13</sup>

The most widely used PCV in the world.<sup>7</sup>

Now approved for older children and adolescents 6 to 17 years of age.<sup>4</sup>



The persons depicted are models used for illustrative purposes only.

Help protect infants and children with the broadest coverage of any PCV by vaccinating them with Prevenar 13<sup>4-6</sup>

## Indication

- Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by *Streptococcus pneumoniae* in infants, children, and adolescents from 6 weeks to 17 years of age

## IMPORTANT SAFETY INFORMATION

- Hypersensitivity (eg, anaphylaxis) to any component of Prevenar 13 or any diphtheria toxoid-containing vaccine is a contraindication to the use of Prevenar 13
- Prevenar 13 does not provide 100% protection against vaccine serotypes nor protect against nonvaccine serotypes
- The frequency of pneumococcal serotypes and serogroups varies geographically, and could influence the effectiveness of the vaccine in any given country
- Because otitis media or pneumonia can be caused by organisms other than the serotypes of *Streptococcus pneumoniae* represented in the vaccine, protection against all otitis media or pneumonia is expected to be lower than for IPD
- The most commonly reported adverse events in children 6 weeks through 17 years were tenderness, redness or swelling at the injection site, irritability, decreased appetite, decreased or increased sleep, and fever. The most commonly reported side effects in children 5 years through 17 years also included hives
- In clinical studies with concomitant administration of Prevenar 13 and rotavirus vaccine, no change in the safety profiles of these vaccines was observed; immunogenicity was not evaluated

1. World Health Organization. Immunization, vaccines and biologicals: pneumococcal disease. <http://www.who.int/immunization/diseases/pneumococcal/en/>. Updated January 24, 2014. Accessed August 4, 2015. 2. World Health Organization. Global immunization data. [http://www.who.int/immunization/monitoring\\_surveillance/Global\\_Immunization\\_Data.pdf?ua=1](http://www.who.int/immunization/monitoring_surveillance/Global_Immunization_Data.pdf?ua=1). Published February 2014. Accessed August 4, 2015. 3. Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep*. 2010;59(RR-11):1-19. 4. Prevenar 13, Summary of Product Characteristics, June 2015. 5. McIntosh EDG, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. *Expert Rev Vaccines*. 2011;10(1):109-129. 6. Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. *Expert Rev Vaccines*. 2010;9(3):229-236. 7. Pfizer Presents Detailed Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPITA) Evaluating Efficacy Of Prevenar 13\* Study Findings, Presented at ISPPD, Demonstrate that Prevenar 13 Can Prevent Vaccine-Type Community-Acquired Pneumonia March 12, 2014. 8. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. *Pediatr Infect Dis J*. 2013;32(3):203-207. 9. Miller E, Andrews NJ, Waight PA, Slack MPE, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. *Vaccine*. 2011;29(49):9127-9131. 10. Steens A, Bergsaker MAR, Aaberge IS, Rønning K, Vestheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. *Vaccine*. 2013;31(52):6232-6238. 11. Dagan R, Greenberg D, Leibovitz E, et al. Trends in serotype-specific pneumococcal carriage in children visiting pediatric emergency room (PER) post PCV7 and PCV13 introduction correlate with trends in serotype-specific otitis media (OM) incidence. Poster presented at: Infectious Disease Week (IDWeek 2013™; October 2-6, 2013; San Francisco, CA. Poster 445. 12. Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. *Lancet Respir Med*. 2014;2(5):387-394. 13. Pirez MC, Algorta G, Chamorro F, et al. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and *Haemophilus influenzae* type b conjugate vaccine in a pediatric referral hospital in Uruguay. *Pediatr Infect Dis J*. 2014;33(7):753-759.

Prevenar 13 is a prescription medicine.

Please refer to full summary of product characteristics before prescribing.

Approval date: August 06, 2015. PVC/2015/001

All rights reserved.

Prevenar 13\*

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)



\*Trademark



## Sponsors

---



## Sponsor of the Congress Materials

---



## Supporters

---

Fresenius Kabi      Sandoz      Noramedia      Ewopharma  
Fonds Medicīnas izglītības un zinātniskās izpētes atbalstam

## Exhibitors

---

Grindeks      Abbvie      German Products      Diamedica      Innothera Baltics  
Solbritt      Bayer      Philips      Sirowa Riga      Childlife      Algol Pharma